Pharma BD Deal Intelligence
Bristol-Myers Company and Squibb Corporation announced a stock-for-stock merger of equals on July 27, 1989 valued at approximately $12-16 billion, closing October 4, 1989 to form Bristol-Myers Squibb Company. At the time, it was the largest pharmaceutical merger in US history and created one of the largest healthcare companies globally, with combined revenues of ~$8.9 billion. Bristol-Myers contributed a diversified portfolio across pharmaceuticals (Cefzil, Buspar), consumer health (Bufferin, Excedrin), Mead Johnson infant nutrition, and Clairol hair care. Squibb brought cardiovascular leadership anchored by Capoten (captopril — the first ACE inhibitor, ~$1.6B peak sales) and Monopril (fosinopril), plus oncology assets including early-stage paclitaxel (later launched as Taxol). Richard Gelb (ex-Bristol-Myers) served as chairman; Richard Furlaud (ex-Squibb) as vice-chairman. The merger pioneered the modern large-pharma consolidation era, preceding SmithKline/Beecham (1989), Glaxo/Burroughs Wellcome (1995), and the broader 1990s-2000s M&A wave.